Aripiprazole
- TRADE NAMES: Abilify (Bristol-Myers Squibb); Abilitat; Aristada (Alkermes)
- INDICATIONS: Schizophrenia, bipolar I disorder, major depressive disorder, irritability associated with autistic disorder
- CLASS: Antipsychotic, Mood stabilizer
- HALF-LIFE: 75–94 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alcohol, Atazanavir, Carbamazepine, CYP3A4 inhibitors, Efavirenz, Itraconazole, Ketoconazole, Lopinavir, Nelfinavir, Paroxetine Hydrochloride, Quinidine
PREGNANCY CATEGORY: C
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
SUICIDALITY AND ANTIDEPRESSANT DRUGS
See full prescribing information for complete boxed warnings.
Please login to see the rest of this drug profile
SKIN.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of aripiprazole in the Informa Healthcare journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 03/15/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric